ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2024

Dec 21, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2024-12-18

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-18	Common Stock	S	12653	$20.52	Disposed	3702394	Direct
2024-12-18	Common Stock	S	8260	$21.74	Disposed	3694134	Direct
2024-12-18	Common Stock	S	5799	$22.12	Disposed	3688335	Direct
2024-12-18	Common Stock	A	100000	—	Acquired	3788335	Direct

Footnotes

F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2: Partial disposition of performance RSUs to satisfy tax withholding obligations. The performance RSUs were subject to a performance condition, which the Compensation Committee of the Company certified as achieved on December 17, 2024.

F3: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $21.11, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

F5: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.18 to $22.04, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F6: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $22.05 to $22.27, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F7: Represents shares underlying restricted stock units with a grant date 12/18/24, which will vest in four equal annual installments.